AR116798A1 - Inhibidores de la replicación del virus de la inmunodeficiencia humana - Google Patents
Inhibidores de la replicación del virus de la inmunodeficiencia humanaInfo
- Publication number
- AR116798A1 AR116798A1 ARP190103016A ARP190103016A AR116798A1 AR 116798 A1 AR116798 A1 AR 116798A1 AR P190103016 A ARP190103016 A AR P190103016A AR P190103016 A ARP190103016 A AR P190103016A AR 116798 A1 AR116798 A1 AR 116798A1
- Authority
- AR
- Argentina
- Prior art keywords
- chf2
- och3
- alkyl
- ethyl
- immunodeficiency virus
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 230000029812 viral genome replication Effects 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 8
- -1 -OCHF2 Chemical group 0.000 abstract 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se definen compuestos de fórmula (1), incluidas las sales farmacéuticamente aceptables de los mismos, y composiciones y procedimientos para tratar la infección por el virus de la inmunodeficiencia humana (VIH). Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en la que: G¹ es fenilo sustituido una vez con -N(CH₃)S(O₂)CH₃, -S(O₂)C(CH₃)₃, -CHF₂, -CF₃, -OCHF₂, -OCF₃ o -C(CH₃)₂OH, con la condición de que cuando G¹ es -CHF₂ o CF₃, G¹ no está en la posición para o G¹ es uno de los compuestos del grupo de fórmulas (2); G² y G³ se seleccionan independientemente entre H o -CH₃; G⁴ es H, -CH₃ u -OCH₃; G⁴ᵃ es -CH₃ u -OCH₃; G⁵ es -CH₃ o CH₂CH₃; G⁶ es H, -CH₃ o CH₂CH₃; G⁷ es etilo, isopropilo, terc-butilo, -CHF₂ o -CF₃; G⁸ es H, metilo, etilo, -CHF₂, -CF₃, -OCH₃ u -OCH₂CH₃; G⁹ es etilo, isopropilo, ciclopropilo, -CH₂OH, -OCH₃; G¹⁰ es etilo, isopropilo, ciclopropilo, terc-butilo, -CHF₂ o -CF₃; G¹¹ es metilo, -OCH₃, -CHF₂, -CF₃, -S(O₂)CH₃; G¹² es F, -CH₃, -CHF₂, -CF₃, -OCH₃, -S(O₂)CH₃; G¹³ es alquilo C₁₋₄, cicloalquilo C₁₋₆, -CH₂O(alquilo C₁₋₃); G¹⁴ es H, alquilo C₁₋₄, -CHF₂, -CF₃, -O(alquilo C₁₋₃); G¹⁵ es H, F, -CH₃ u OCH₃; R³ es H, F, Cl, -CH₃ u -OCH₃; R⁴ es H o alquilo C₁₋₃ en donde el alquilo C₁₋₃ está opcionalmente sustituido con 1 - 3 flúor; R⁵ es alquilo C₁₋₆ o cicloalquilo C₃₋₆; W se selecciona entre: los compuestos del grupo de fórmulas (3), en las que R⁶ es metilo opcionalmente sustituido con 1 a 3 flúor.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749818P | 2018-10-24 | 2018-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR116798A1 true AR116798A1 (es) | 2021-06-16 |
Family
ID=68344933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103016A AR116798A1 (es) | 2018-10-24 | 2019-10-22 | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11541055B2 (es) |
| EP (1) | EP3870577A1 (es) |
| JP (1) | JP7398448B2 (es) |
| KR (1) | KR20210084508A (es) |
| CN (1) | CN113195475A (es) |
| AR (1) | AR116798A1 (es) |
| AU (1) | AU2019364739B2 (es) |
| BR (1) | BR112021007362A2 (es) |
| CA (1) | CA3117289A1 (es) |
| CL (1) | CL2021001025A1 (es) |
| CO (1) | CO2021004679A2 (es) |
| CR (1) | CR20210207A (es) |
| DO (1) | DOP2021000062A (es) |
| EA (1) | EA202190854A1 (es) |
| IL (1) | IL282240A (es) |
| MA (1) | MA53973A (es) |
| MX (1) | MX2021004593A (es) |
| PE (1) | PE20211781A1 (es) |
| PH (1) | PH12021550813A1 (es) |
| SG (1) | SG11202103560YA (es) |
| TW (1) | TWI824041B (es) |
| WO (1) | WO2020084492A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019198024A1 (en) * | 2018-04-11 | 2019-10-17 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| JP7398448B2 (ja) * | 2018-10-24 | 2023-12-14 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| US20220370451A1 (en) * | 2019-10-08 | 2022-11-24 | VIIV HEALTHCARE UK ( No. 5) LIMITED | Inhibitors of human immunodeficiency virus replication |
| WO2021107066A1 (ja) | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬 |
| CA3164528A1 (en) | 2019-12-09 | 2021-06-17 | Viiv Healthcare Company | Pharmaceutical compositions comprising cabotegravir |
| AU2022362855A1 (en) | 2021-10-13 | 2024-05-02 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7749992B2 (en) | 2003-10-08 | 2010-07-06 | Eli Lilly And Company | Compounds and methods for treating dislipidemia |
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| JP2012201642A (ja) * | 2011-03-25 | 2012-10-22 | Tsutomu Takeuchi | １−フェニルピロリジン−２，５−ジオン誘導体を有効成分とするｂａｆｆの結合阻害剤 |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| ES2614053T3 (es) | 2013-01-09 | 2017-05-29 | Gilead Sciences, Inc. | Heteroarilos de 5 miembros y su uso como antivirales |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| NZ727792A (en) | 2013-01-09 | 2018-04-27 | Gilead Sciences Inc | Therapeutic compounds |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| AU2015306779B2 (en) * | 2014-08-27 | 2017-11-02 | VIIV Healthcare UK (NO.5) Ltd | Imidazo[1,2-a]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication |
| AU2015308907B2 (en) | 2014-08-29 | 2018-10-18 | Gilead Sciences, Inc. | Antiretroviral agents |
| UY37367A (es) | 2016-08-19 | 2018-03-23 | Gilead Sciences Inc | Nuevos compuestos para uso en el tratamiento de una infección viral y composiciones de los mismos |
| UY37710A (es) | 2017-05-02 | 2018-11-30 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| EP3752495B1 (en) | 2018-02-15 | 2023-07-19 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
| AR114631A1 (es) | 2018-02-16 | 2020-09-30 | Gilead Sciences Inc | Métodos e intermedios para preparar compuestos de piridina |
| WO2019198024A1 (en) * | 2018-04-11 | 2019-10-17 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| WO2020031112A1 (en) | 2018-08-09 | 2020-02-13 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3849982A1 (en) | 2018-09-14 | 2021-07-21 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3853228A1 (en) | 2018-09-20 | 2021-07-28 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| FR3086760A1 (fr) | 2018-10-02 | 2020-04-03 | Institut Mines Telecom | Procede d'evaluation de la resistance mecanique d'un echantillon de tissu biologique |
| WO2020084491A1 (en) | 2018-10-24 | 2020-04-30 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| JP7398448B2 (ja) * | 2018-10-24 | 2023-12-14 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| US20210393633A1 (en) | 2018-10-25 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| ES2969030T3 (es) | 2018-10-29 | 2024-05-16 | Viiv Healthcare Uk No 5 Ltd | Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana |
| US20210379071A1 (en) | 2018-11-05 | 2021-12-09 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3877387A1 (en) | 2018-11-05 | 2021-09-15 | ViiV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| UY38559A (es) | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| US11429555B2 (en) | 2019-02-26 | 2022-08-30 | Apple Inc. | Coprocessors with bypass optimization, variable grid architecture, and fused vector operations |
| CN112074195A (zh) | 2019-04-11 | 2020-12-11 | 高丽营养有限公司 | 苹果醋营养补充剂 |
| EP3962603A1 (en) | 2019-04-30 | 2022-03-09 | ViiV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US20210323967A1 (en) | 2019-06-19 | 2021-10-21 | Viiv Healthcare Uk (No. 5) Limited | Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication |
| JP2022551256A (ja) | 2019-10-01 | 2022-12-08 | ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド | ヒト免疫不全ウイルスの複製阻害剤 |
| US20220389007A1 (en) | 2019-10-01 | 2022-12-08 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| TW202128648A (zh) | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| JP2023517312A (ja) | 2020-03-06 | 2023-04-25 | ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド | ヒト免疫不全ウイルスの複製阻害剤 |
-
2019
- 2019-10-22 JP JP2021522518A patent/JP7398448B2/ja active Active
- 2019-10-22 MA MA053973A patent/MA53973A/fr unknown
- 2019-10-22 CR CR20210207A patent/CR20210207A/es unknown
- 2019-10-22 US US16/762,209 patent/US11541055B2/en active Active
- 2019-10-22 AR ARP190103016A patent/AR116798A1/es unknown
- 2019-10-22 TW TW108138086A patent/TWI824041B/zh active
- 2019-10-22 MX MX2021004593A patent/MX2021004593A/es unknown
- 2019-10-22 CN CN201980085915.8A patent/CN113195475A/zh active Pending
- 2019-10-22 EA EA202190854A patent/EA202190854A1/ru unknown
- 2019-10-22 PE PE2021000571A patent/PE20211781A1/es unknown
- 2019-10-22 AU AU2019364739A patent/AU2019364739B2/en active Active
- 2019-10-22 SG SG11202103560YA patent/SG11202103560YA/en unknown
- 2019-10-22 BR BR112021007362-0A patent/BR112021007362A2/pt unknown
- 2019-10-22 WO PCT/IB2019/059020 patent/WO2020084492A1/en unknown
- 2019-10-22 CA CA3117289A patent/CA3117289A1/en active Pending
- 2019-10-22 EP EP19794683.3A patent/EP3870577A1/en active Pending
- 2019-10-22 KR KR1020217015003A patent/KR20210084508A/ko active Search and Examination
-
2021
- 2021-04-08 PH PH12021550813A patent/PH12021550813A1/en unknown
- 2021-04-09 DO DO2021000062A patent/DOP2021000062A/es unknown
- 2021-04-11 IL IL282240A patent/IL282240A/en unknown
- 2021-04-14 CO CONC2021/0004679A patent/CO2021004679A2/es unknown
- 2021-04-22 CL CL2021001025A patent/CL2021001025A1/es unknown
-
2022
- 2022-09-30 US US17/957,569 patent/US20230109662A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2021000062A (es) | 2021-09-15 |
| CO2021004679A2 (es) | 2021-04-30 |
| TW202031261A (zh) | 2020-09-01 |
| CN113195475A (zh) | 2021-07-30 |
| US11541055B2 (en) | 2023-01-03 |
| TWI824041B (zh) | 2023-12-01 |
| KR20210084508A (ko) | 2021-07-07 |
| IL282240A (en) | 2021-05-31 |
| PH12021550813A1 (en) | 2021-10-04 |
| CL2021001025A1 (es) | 2021-11-05 |
| CR20210207A (es) | 2021-09-02 |
| US20230109662A1 (en) | 2023-04-06 |
| US20200360384A1 (en) | 2020-11-19 |
| AU2019364739B2 (en) | 2022-05-26 |
| EP3870577A1 (en) | 2021-09-01 |
| WO2020084492A1 (en) | 2020-04-30 |
| JP2022505841A (ja) | 2022-01-14 |
| JP7398448B2 (ja) | 2023-12-14 |
| EA202190854A1 (ru) | 2021-08-17 |
| BR112021007362A2 (pt) | 2021-07-20 |
| CA3117289A1 (en) | 2020-04-30 |
| MX2021004593A (es) | 2021-06-15 |
| MA53973A (fr) | 2022-02-09 |
| SG11202103560YA (en) | 2021-05-28 |
| AU2019364739A1 (en) | 2021-05-20 |
| PE20211781A1 (es) | 2021-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116798A1 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| ECSP20001149A (es) | Compuestos antiproliferativos y métodos para utilizarlos | |
| PE20230376A1 (es) | Compuestos moduladores de la diacilglicerol quinasa | |
| UY38059A (es) | Heterociclos sustituidos como agentes antivirales | |
| UY37710A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| AR106041A1 (es) | Moduladores de la proteína core de la hepatitis b | |
| AR088097A1 (es) | Compuestos herbicidas | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| UY36649A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| AR066095A1 (es) | Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla | |
| AR095192A1 (es) | Quinolina y quinazolinamidas como modulares de canales de sodio | |
| BR112015021027A8 (pt) | compostos terapêuticos, seus usos, e composições farmacêuticas | |
| AR111315A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR095034A1 (es) | El uso de los agonistas del receptor 2 del péptido formilo para el tratamiento de las enfermedades inflamatorias oculares | |
| AR103251A1 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| AR107927A1 (es) | Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento | |
| AR102427A1 (es) | Derivados de carbazol inhibidores de quinasas | |
| AR105875A1 (es) | Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominio | |
| AR104512A1 (es) | Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap) | |
| AR104963A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| AR120246A1 (es) | Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 | |
| AR112831A1 (es) | Terapia de combinación usando un antagonista del receptor 2 de quimiocina (ccr2) y un inhibidor de pd-1 / pd-l1 | |
| CR20180091A (es) | 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih | |
| AR098723A1 (es) | Derivados de pirazolopirimidin-2-ilo como inhibidores de jak |